Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 6:12:453-461.
doi: 10.2147/OPTH.S157853. eCollection 2018.

Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease

Antonio José Mateo Orobia  1 , Jorge Saa  2 , Alberto Ollero Lorenzo  3 , José María Herreras  4   5
Affiliations
Review

Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease

Antonio José Mateo Orobia et al. Clin Ophthalmol. .

Abstract

Background: Dry Eye Disease (DED) is a multifactorial disease, with a high prevalence, that can have a great impact on the quality of life of patients. The first step of treatment includes the use of lacrimal substitutes composed of polymers, possible to associate osmoprotectant agents to the lacrimal substitutes. The aim of this article is to analyze the properties of the combination of hyaluronic acid (HA), carmellose, and osmoprotectors (Optava Fusion®; Allergan, Inc., Irvine, CA, USA) on DED. General considerations on the use of artificial tears are also proposed.

Methods: A group of ophthalmologists, experts in the management of the ocular surface, analyzed different aspects related to DED; among them, the use of artificial tears in general and the properties of the combination of HA, carmellose, and osmoprotectors, in particular, were discussed. A review of the literature was carried out, which included different articles published in Spanish, English, and French until April 2017.

Conclusions: DED is a common chronic pathology that usually requires sustained treatment. In addition, the combination of HA, carmellose, and osmoprotectors has proven to be effective in the treatment of symptoms and signs of dry eye by the synergistic action of all its components. This review provides key elements to help ophthalmologists who begin in the management of DED.

Keywords: artificial tears; carmellose; dry eye disease; hyaluronic acid; hyperosmolarity; osmoprotectants.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Mechanism of action of the different components of the fixed combined formulation of HA, CMC, and osmoprotectants (Optava Fusion®; Allergan, Inc., Irvine, CA, USA). Abbreviations: CMC, carboxymethyl cellulose; HA, hyaluronic acid; MMP, matrix metalloproteinases.
See this image and copyright information in PMC

References

    1. Bjerrum KB. Keratoconjunctivitis sicca and primary Sjögren’s syndrome in a Danish population aged 30–60 years. Acta Ophthalmol Scand. 1997;75(3):281–286. - PubMed
    1. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105(6):1114–1119. - PubMed
    1. Versura P, Cellini M, Torreggiani A, Profazio V, Bernabini B, Caramazza R. Dryness symptoms, diagnostic protocol and therapeutic management: a report on 1,200 patients. Ophthalmic Res. 2001;33(4):221–227. - PubMed
    1. Viso E, Rodriguez-Ares MT, Gude F. Prevalence of and associated factors for dry eye in a Spanish adult population (the Salnes Eye Study) Ophthalmic Epidemiol. 2009;16(1):15–21. - PubMed
    1. Young G, Chalmers RL, Napier L, Hunt C, Kern J. Characterizing contact lens-related dryness symptoms in a cross-section of UK soft lens wearers. Cont Lens Anterior Eye. 2011;34(2):64–70. - PubMed

LinkOut - more resources